focus on coping skills and body neutrality
Retatrutide is an investigational once-weekly agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors
SURPASS-2 results (40 weeks, type 2 diabetes): Tirzepatide 5 mg: -7.6 kg weight loss, -2.01% HbA1c reduction Tirzepatide 10 mg: -9.3 kg weight loss, -2.24% HbA1c reduction Tirzepatide 15 mg: -11.2 kg weight loss, -2.30% HbA1c reduction Semaglutide 1 mg: -5.7 kg weight loss, -1.86% HbA1c reduction SURMOUNT-5 results (72 weeks, obesity): Tirzepatide demonstrated statistically superior weight loss compared to semaglutide 2.4 mg
Being overweight also puts more stress on the kidneys, making it harder for them to remove uric acid from the body
Zinc: The Japanese semaglutide study that found B12 decline also documented significant zinc decreases
In February 2025, the company got approval to market Wegovy for additional indications like reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
